John Bencich
2020
In 2020, John Bencich earned a total compensation of $883.7K as Chief Executive Officer and Former Chief Financial Officer and Chief Operating Officer at OncoGenex Pharmaceuticals, a 55% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $199,610 |
|---|---|
| Option Awards | $263,208 |
| Salary | $420,914 |
| Total | $883,732 |
Bencich received $420.9K in salary, accounting for 48% of the total pay in 2020.
Bencich also received $199.6K in non-equity incentive plan and $263.2K in option awards.
Rankings
In 2020, John Bencich's compensation ranked 9,118th out of 13,090 executives tracked by ExecPay. In other words, Bencich earned more than 30.3% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 9,118 out of 13,090 | 30th |
Division Manufacturing | 3,898 out of 5,621 | 31st |
Major group Chemicals And Allied Products | 1,579 out of 2,254 | 30th |
Industry group Drugs | 1,380 out of 1,954 | 29th |
Industry In Vitro and In Vivo Diagnostic Substances | 39 out of 60 | 35th |
Source: SEC filing on March 30, 2021.
Bencich's colleagues
We found two more compensation records of executives who worked with John Bencich at OncoGenex Pharmaceuticals in 2020.
News
OncoGenex Pharmaceuticals CEO John Bencich's 2022 pay slips 7% to $1.5M
April 28, 2023
OncoGenex Pharmaceuticals CEO John Bencich's 2021 pay jumps 82% to $1.6M
April 21, 2022
OncoGenex Pharmaceuticals CEO Richard Stewart's 2020 pay jumps 30% to $1M
March 30, 2021
OncoGenex Pharmaceuticals CEO Richard Stewart's 2019 pay falls 27% to $797K
April 2, 2020
OncoGenex Pharmaceuticals CEO Richard Stewart's 2018 pay jumps 423% to $1.1M
March 28, 2019